Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A06AH04
|
| gptkbp:brand |
gptkb:Movantik
|
| gptkbp:CASNumber |
99574-57-9
|
| gptkbp:chemicalFormula |
C34H51NO11
|
| gptkbp:contraindication |
known or suspected gastrointestinal obstruction
|
| gptkbp:drugClass |
opioid
|
| gptkbp:eliminationHalfLife |
6-11 hours
|
| gptkbp:genericName |
gptkb:naloxegol
|
| https://www.w3.org/2000/01/rdf-schema#label |
Movantik
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:RedHill_Biopharma
gptkb:AstraZeneca |
| gptkbp:mechanismOfAction |
peripherally acting mu-opioid receptor antagonist
|
| gptkbp:metabolism |
gptkb:CYP3A4
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:proteinBinding |
~45%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain flatulence |
| gptkbp:usedFor |
opioid-induced constipation
|
| gptkbp:bfsParent |
gptkb:AstraZeneca_US
|
| gptkbp:bfsLayer |
6
|